Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
NNRTI (HIV)

Rilpivirine

Brand names: Edurant

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used as part of combination antiretroviral therapy for HIV-1 infection.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds to and inhibits HIV-1 reverse transcriptase, blocking transcription of viral RNA into DNA.

Prescribing in practice

  • Acid-reducing agents such as proton pump inhibitors are contraindicated because they markedly reduce rilpivirine absorption and risk virological failure.
  • It should be taken with a meal to ensure adequate absorption.
  • Efficacy is reduced in patients with a high baseline viral load, so it is preferred for those with lower viral loads.

Monitoring

Monitor HIV viral load and CD4 count to confirm virological response, with attention to adherence and food intake.

Counselling the patient

  • Always take this medicine with a meal, not on an empty stomach.
  • Do not use proton pump inhibitor indigestion remedies; check other antacids with your clinician.
  • Take every dose to keep the virus under control and prevent resistance.

Evidence & guidelines

Rilpivirine is an established NNRTI option in UK and international HIV treatment guidelines for appropriate patients.

Reference: BHIVA; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Pathways